ZA963854B - Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids. - Google Patents

Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids.

Info

Publication number
ZA963854B
ZA963854B ZA9603854A ZA963854A ZA963854B ZA 963854 B ZA963854 B ZA 963854B ZA 9603854 A ZA9603854 A ZA 9603854A ZA 963854 A ZA963854 A ZA 963854A ZA 963854 B ZA963854 B ZA 963854B
Authority
ZA
South Africa
Prior art keywords
oral dosage
omega
inflammatory bowel
bowel disease
treatment
Prior art date
Application number
ZA9603854A
Other languages
English (en)
Inventor
Thomas Buser
Emilio Paolo Camporesi
Original Assignee
Tillotts Pharma A G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma A G filed Critical Tillotts Pharma A G
Publication of ZA963854B publication Critical patent/ZA963854B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9603854A 1995-05-15 1996-05-15 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids. ZA963854B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9509764.8A GB9509764D0 (en) 1995-05-15 1995-05-15 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids

Publications (1)

Publication Number Publication Date
ZA963854B true ZA963854B (en) 1997-11-17

Family

ID=10774461

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9603854A ZA963854B (en) 1995-05-15 1996-05-15 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids.

Country Status (23)

Country Link
US (2) US5792795A (de)
EP (1) EP0825858B1 (de)
JP (1) JPH11509523A (de)
KR (1) KR100427112B1 (de)
CN (1) CN1104237C (de)
AT (1) ATE294575T1 (de)
AU (1) AU702692B2 (de)
BR (1) BR9608785A (de)
CA (1) CA2221356C (de)
CZ (1) CZ288560B6 (de)
DE (1) DE69634693T2 (de)
DK (1) DK0825858T3 (de)
ES (1) ES2240995T3 (de)
GB (1) GB9509764D0 (de)
HU (1) HU227282B1 (de)
IL (1) IL118240A (de)
NO (1) NO320780B1 (de)
PL (1) PL184085B1 (de)
PT (1) PT825858E (de)
SK (1) SK282062B6 (de)
TW (1) TW397683B (de)
WO (1) WO1996036329A1 (de)
ZA (1) ZA963854B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
KR100569319B1 (ko) * 1997-10-30 2006-04-07 모리시타 진탄 가부시키가이샤 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
IL137734A0 (en) * 1998-02-11 2001-10-31 Res Triangle Pharm Ltd Method and composition for treatment of inflammatory conditions
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
DE19930030B4 (de) * 1999-06-30 2004-02-19 Meduna Arzneimittel Gmbh CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US20040091545A1 (en) * 2000-12-06 2004-05-13 Justin Slagel Solid polyunsaturated fatty acid compositions
US6548646B1 (en) * 2001-08-23 2003-04-15 Bio-Rad Laboratories, Inc. Reference control for high-sensitivity C-reactive protein testing
AU2002352726A1 (en) * 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
SE0202188D0 (sv) * 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
EP2295529B2 (de) * 2002-07-11 2022-05-18 Basf As Verfahren zur Verminderung von Umweltschadstoffen in einem Öl oder einem Fett und Fischfutterprodukt
AU2002951913A0 (en) * 2002-10-08 2002-10-24 Chevis Agriservices & Consulting Pty. Limited Method of treatment
US20050152969A1 (en) * 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0413729D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US8758814B2 (en) 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
WO2009009040A2 (en) * 2007-07-06 2009-01-15 Baum Seth J Fatty acid compositions and methods of use
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2334295B1 (de) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzung mit eicosapentaensäure und nikotinsäure und anwendungsverfahren dafür
US20100130608A1 (en) * 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
WO2010119319A1 (en) 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
US9901551B2 (en) * 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP3318255B1 (de) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Zusammensetzungen und verfahren zur behandlung des schlaganfalles bei patienten mit gleichzeitiger statin-therapie
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
AU2010309517B2 (en) * 2009-10-23 2016-10-20 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
EA201370099A1 (ru) 2010-10-19 2013-11-29 Элселикс Терапьютикс, Инк. Терапия на основе лигандов хемосенсорных рецепторов
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8551551B2 (en) 2012-01-06 2013-10-08 Perlman Consulting, Llc Stabilization of omega-3 fatty acids in saturated fat microparticles having low linoleic acid content
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
HK1206248A1 (en) 2012-05-07 2016-01-08 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
NZ727849A (en) 2012-06-29 2018-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
EP2745709A1 (de) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Nahrungsmittelzusammensetzungen mit reduziertem Beta-Casein-A1 und zugehörige Verfahren
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
JP2017534627A (ja) 2014-11-06 2017-11-24 ノースウエスタン ユニバーシティＮｏｒｔｈｗｅｓｔｅｒｎ Ｕｎｉｖｅｒｓｉｔｙ 癌細胞運動性の阻害
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
FR3061019B1 (fr) * 2016-12-26 2019-05-24 Belles Feuilles Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments.
FR3061151B1 (fr) * 2016-12-26 2019-05-24 Belles Feuilles Procede et systeme pour conditionner un compose lipidique en doses, capsules de compose lipidique ainsi obtenues et applications de ces capsules.
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
KR200490037Y1 (ko) 2019-04-17 2019-09-11 트랜드 주식회사 원터치 작동방식 욕실 청소용 물분사 헤드
US12342842B2 (en) 2019-05-23 2025-07-01 Evonik Operations Gmbh Preparation for use in enhancing formation of short-chain fatty acids (SCFAs)
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8505569D0 (sv) * 1985-11-25 1985-11-25 Aco Laekemedel Ab Enteralt preparat
EP0289204B1 (de) * 1987-04-27 1991-07-17 Efamol Holdings Plc Lithiumsalze enthaltende pharmazeutische Zubereitungen
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
CA2150019C (en) * 1992-11-30 1999-01-05 Scott M. Herbig Supported liquid membrane delivery devices
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids

Also Published As

Publication number Publication date
IL118240A0 (en) 1996-09-12
AU702692B2 (en) 1999-03-04
IL118240A (en) 2001-01-28
SK152397A3 (en) 1998-05-06
DK0825858T3 (da) 2005-08-15
NO320780B1 (no) 2006-01-30
EP0825858A1 (de) 1998-03-04
US5792795A (en) 1998-08-11
BR9608785A (pt) 1999-07-06
NO975218D0 (no) 1997-11-13
KR19990014767A (ko) 1999-02-25
WO1996036329A1 (en) 1996-11-21
EP0825858B1 (de) 2005-05-04
ATE294575T1 (de) 2005-05-15
CN1184421A (zh) 1998-06-10
CA2221356A1 (en) 1996-11-21
CZ288560B6 (cs) 2001-07-11
SK282062B6 (sk) 2001-10-08
NO975218L (no) 1997-11-13
HUP9900337A2 (hu) 1999-06-28
HU227282B1 (en) 2011-01-28
GB9509764D0 (en) 1995-07-05
CZ360797A3 (cs) 1998-06-17
CA2221356C (en) 2003-12-30
AU5895596A (en) 1996-11-29
DE69634693T2 (de) 2006-05-04
CN1104237C (zh) 2003-04-02
DE69634693D1 (de) 2005-06-09
HUP9900337A3 (en) 2001-12-28
KR100427112B1 (ko) 2004-09-16
PT825858E (pt) 2005-08-31
US5948818A (en) 1999-09-07
ES2240995T3 (es) 2005-10-16
TW397683B (en) 2000-07-11
JPH11509523A (ja) 1999-08-24
PL323362A1 (en) 1998-03-30
MX9708758A (es) 1998-03-31
PL184085B1 (pl) 2002-08-30

Similar Documents

Publication Publication Date Title
IL118240A0 (en) Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
ATE202473T1 (de) Rasch freisetzende tablettenkerne mit unlöslichen arzneistoffen und mit einem retardüberzug
CA2065809A1 (en) Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
KR920000324A (ko) 필수 지방산 처리법
CA2065652A1 (en) Controlled release gastroresistant pharmaceutical formulations for oral administration containing bile acids and their salts
EP2263660A3 (de) Im Munde zerfallende Tablette
ATE30380T1 (de) Pharmazeutische formulierungen mit mehrfachen einheiten.
CA2304948A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease
PL327323A1 (en) Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases
MY114610A (en) Controlled drug delivery system for diltiazem.